Scandion Oncology announces share purchase by Board of Directors and Executive Management

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that members of the Board of Directors and Executive Management have purchased shares in the company.

The following share purchases have been reported:

Shares purchased Total shareholding
Peter Høngaard Andersen Chairman of the Board 6,500 59,565
Jørgen Bardenfleth Vice-chairman of the Board 15,000 425,629
Christian Vinding Thomsen Board member 10,000 10,000
Thomas Feldthus Board member 10,000 28,182
Martin Møller Board member 4,700 4,700
Bo Rode Hansen Board member & CEO 2,042 42,442
Annie Rasmussen Employee representative 1,205 20,000

Persons under an obligation to report are defined as members of the Board of Directors and members of Executive Management.

For further information regarding Scandion Oncology, please contact:

Bo Rode Hansen, President & CEO

Phone: +45 3810 2017



The information was provided by the contact person above for publication on November 22, 2021, at 17.30 CET.

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at or +46 (0) 40 200 250.